[go: up one dir, main page]

EE200200181A - April retseptor ja selle kasutamine - Google Patents

April retseptor ja selle kasutamine

Info

Publication number
EE200200181A
EE200200181A EEP200200181A EEP200200181A EE200200181A EE 200200181 A EE200200181 A EE 200200181A EE P200200181 A EEP200200181 A EE P200200181A EE P200200181 A EEP200200181 A EE P200200181A EE 200200181 A EE200200181 A EE 200200181A
Authority
EE
Estonia
Prior art keywords
april
april receptor
receptor
antibodies
methods
Prior art date
Application number
EEP200200181A
Other languages
English (en)
Inventor
Schneider Pascal
Thompson Jeffrey
Cachero Teresa
Ambrose Christine
Rennert Paul
Original Assignee
Biogen, Inc.
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200181(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc., Apotech R & D Sa filed Critical Biogen, Inc.
Publication of EE200200181A publication Critical patent/EE200200181A/et
Publication of EE05212B1 publication Critical patent/EE05212B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200181A 1999-10-06 2000-10-05 Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i EE05212B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15793399P 1999-10-06 1999-10-06
US18180700P 2000-02-11 2000-02-11
US21568800P 2000-06-30 2000-06-30
PCT/US2000/027579 WO2001024811A1 (en) 1999-10-06 2000-10-05 April receptor (bcma) and uses thereof

Publications (2)

Publication Number Publication Date
EE200200181A true EE200200181A (et) 2003-06-16
EE05212B1 EE05212B1 (et) 2009-10-15

Family

ID=27388102

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200181A EE05212B1 (et) 1999-10-06 2000-10-05 Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i

Country Status (30)

Country Link
US (1) US7276241B2 (et)
EP (3) EP2324844A3 (et)
JP (2) JP4880155B2 (et)
KR (1) KR100759295B1 (et)
CN (1) CN1263507C (et)
AT (1) ATE360434T1 (et)
AU (1) AU776852B2 (et)
BG (1) BG65473B1 (et)
BR (1) BR0014583A (et)
CA (1) CA2386463C (et)
CZ (1) CZ297633B6 (et)
DE (1) DE60034586T2 (et)
DK (1) DK1223964T3 (et)
EA (1) EA005601B1 (et)
EE (1) EE05212B1 (et)
GE (1) GEP20043375B (et)
HK (1) HK1044710B (et)
HU (1) HUP0203567A2 (et)
IL (3) IL148839A0 (et)
IS (1) IS6322A (et)
MX (1) MXPA02003393A (et)
NO (1) NO331683B1 (et)
NZ (1) NZ517907A (et)
PL (1) PL204010B1 (et)
RS (1) RS51602B (et)
SK (1) SK286331B6 (et)
TR (1) TR200200912T2 (et)
UA (1) UA74798C2 (et)
WO (1) WO2001024811A1 (et)
ZA (1) ZA200202578B (et)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
KR20090016772A (ko) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
DK1666052T3 (da) * 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
ES2287130T3 (es) 2000-05-12 2007-12-16 Amgen Inc. Polipeptidos para inhibir la proliferacion de celulas b y t inducida por april.
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1401870A4 (en) * 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
IL160127A0 (en) * 2001-08-03 2004-06-20 Genentech Inc Tacis and br3 polypeptides and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003068977A2 (de) 2002-02-10 2003-08-21 Apoxis Sa Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
JP2005533863A (ja) * 2002-07-25 2005-11-10 ジェネンテック・インコーポレーテッド Ｔａｃｉ抗体とその用途
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP2272868B1 (en) * 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
CA2543093A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for baff antagonists
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CN1786016B (zh) * 2004-12-09 2010-12-29 中国人民解放军军事医学科学院基础医学研究所 一种人工构建的生物活性分子及其制备方法
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
DE602006007323D1 (de) * 2005-01-28 2009-07-30 Biogen Idec Inc VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
MX2008001661A (es) 2005-08-09 2008-04-07 Ares Trading Sa Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion del activador de transmembrana o interactor del ligando de ciclofilina de modulacion de calcio-ig.
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
MX2008014365A (es) 2006-05-15 2008-11-27 Ares Trading Sa Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
DK2061814T3 (da) 2006-10-27 2012-08-27 Genentech Inc Antistoffer og immunokonjugater og anvendelse deraf.
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
DK2953972T3 (da) 2013-02-05 2020-10-12 Engmab Sarl Fremgangsmåde til udvælgelse af antistoffer mod bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2971077B1 (en) 2013-03-15 2019-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
CA2929774C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animal cells having a humanized proliferation-inducing ligand gene
WO2016003876A1 (en) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
LT3331910T (lt) 2015-08-03 2020-03-25 Engmab Sarl Monokloniniai antikūnai prieš žmogaus b ląstelių brendimo antigeną (bcma)
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
AU2016353067B2 (en) * 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
IL313508A (en) 2015-11-25 2024-08-01 Visterra Inc Antibody molecules to april and uses thereof
SG11201806261XA (en) 2016-02-17 2018-09-27 Seattle Genetics Inc Bcma antibodies and use of same to treat cancer and immunological disorders
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3100118A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
JP7439046B2 (ja) 2018-07-20 2024-02-27 テネオツー・インコーポレイテッド Ｃｄ１９に結合する重鎖抗体
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EA202192736A1 (ru) 2019-04-05 2022-01-27 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с псма
CN121293351A (zh) 2019-05-21 2026-01-09 诺华股份有限公司 Cd19结合分子及其用途
BR112021024956A2 (pt) 2019-06-14 2022-01-25 Teneobio Inc Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
KR20220068984A (ko) 2019-07-30 2022-05-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
TWI894270B (zh) 2020-05-11 2025-08-21 美商健生生物科技公司 用於治療多發性骨髓瘤之方法
JP2023527563A (ja) * 2020-05-29 2023-06-29 チヌーク セラピューティクス，インコーポレイテッド ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
AU2021300179A1 (en) 2020-06-30 2023-02-02 Teneobio, Inc. Multi-specific antibodies binding to BCMA
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
CA3228678A1 (en) 2021-08-11 2023-02-16 Amato J. Giaccia Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025174963A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134480A0 (en) * 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
IL134537A0 (en) * 1997-09-12 2001-04-30 Apotech Sa Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
CN101518648A (zh) * 1999-01-07 2009-09-02 津莫吉尼蒂克斯公司 可溶性受体br43×2和应用方法
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
EP1415659B9 (en) 1999-01-25 2012-02-15 Biogen Idec MA Inc. An antibody specific for soluble BAFF for use in the treatment of cancer
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU777536B2 (en) 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
JP2002541779A (ja) * 1999-02-24 2002-12-10 ザ ジュネラル ホスピタル コーポレーション シグナル伝達中間体のクローニング方法
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
KR20090016772A (ko) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
DK1666052T3 (da) * 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
ES2287130T3 (es) 2000-05-12 2007-12-16 Amgen Inc. Polipeptidos para inhibir la proliferacion de celulas b y t inducida por april.
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
EP1309718A4 (en) 2000-08-15 2004-08-25 Human Genome Sciences Inc NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002364954A1 (en) 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Also Published As

Publication number Publication date
IL204401A (en) 2014-12-31
CA2386463C (en) 2012-02-07
CN1399556A (zh) 2003-02-26
EP1223964B1 (en) 2007-04-25
EA005601B1 (ru) 2005-04-28
PL355102A1 (en) 2004-04-05
KR100759295B1 (ko) 2007-09-18
BR0014583A (pt) 2002-06-11
MXPA02003393A (es) 2004-08-19
HUP0203567A2 (hu) 2003-02-28
JP2003510366A (ja) 2003-03-18
NO20021594L (no) 2002-06-05
EA200200427A1 (ru) 2002-12-26
NZ517907A (en) 2004-01-30
BG65473B1 (bg) 2008-09-30
BG106670A (en) 2002-12-29
RS51602B (sr) 2011-08-31
KR20020053066A (ko) 2002-07-04
DK1223964T3 (da) 2007-08-27
DE60034586D1 (de) 2007-06-06
EE05212B1 (et) 2009-10-15
EP2324844A3 (en) 2013-12-11
CN1263507C (zh) 2006-07-12
SK4512002A3 (en) 2002-12-03
TR200200912T2 (tr) 2002-07-22
IL148839A0 (en) 2002-09-12
ZA200202578B (en) 2003-07-02
NO331683B1 (no) 2012-02-20
IS6322A (is) 2002-03-22
EP2324844A2 (en) 2011-05-25
JP2011079863A (ja) 2011-04-21
GEP20043375B (en) 2004-11-25
AU7864500A (en) 2001-05-10
DE60034586T2 (de) 2008-02-28
PL204010B1 (pl) 2009-12-31
WO2001024811A1 (en) 2001-04-12
HK1044710B (en) 2007-12-07
EP1223964A1 (en) 2002-07-24
US7276241B2 (en) 2007-10-02
UA74798C2 (uk) 2006-02-15
CZ20021169A3 (cs) 2002-09-11
ATE360434T1 (de) 2007-05-15
CZ297633B6 (cs) 2007-02-14
IL148839A (en) 2015-01-29
US20030082175A1 (en) 2003-05-01
JP4880155B2 (ja) 2012-02-22
NO20021594D0 (no) 2002-04-04
YU25302A (sh) 2005-06-10
SK286331B6 (en) 2008-07-07
AU776852B2 (en) 2004-09-23
CA2386463A1 (en) 2001-04-12
EP1847273A1 (en) 2007-10-24
HK1044710A1 (en) 2002-11-01

Similar Documents

Publication Publication Date Title
EE200200181A (et) April retseptor ja selle kasutamine
SK500172015A3 (et)
EP1151002A4 (en) KDR-SPECIFIC ANTIBODIES AND USES THEREOF
DE69925122D1 (de) Hülse zur verwendung mit ultraschallsonde
DE69535459D1 (de) Monoklonale antikörper spezifisch gegen vegf-rezeptoren und ihre verwendung
ATE451460T1 (de) Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
DE60129572D1 (de) Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
FI913427A0 (fi) Molekyylit, joissa on vasta-ainetta liittävät kohdat ja joilla on stereospesifinen katalyysi
PT948491E (pt) Derivados de aminotiazole uteis na preparacao de antibioticos beta-lactamicos
FI1828U1 (fi) Naturstenselement foer anvaendning i samband med vaermare
FI1829U1 (fi) Naturstenselement foer anvaendning i samband med vaermare
SE9402150D0 (sv) Methods and means to obtain streptococcal proteins and the use of the genes encoding these proteins
KR970054631U (ko) 길이를 늘려 사용가능한 용기

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20161005